RNA nanostructures, methods of making, and uses thereof

Patent metadata

Field	Value
Publication number	US-11976092-B2
Application number	US-201816635312-A
Country	US
Kind code	B2
Filing date	Nov 12, 2018
Priority date	Feb 9, 2018
Publication date	May 7, 2024
Grant date	May 7, 2024

Abstract

Disclosed herein are high Tm RNA nanostructures that can be composed of one or more modules or motifs to build RNA nanostructures with or without layers. The RNA nanostructures can have a core domain and three or more double-stranded arms and formulations thereof to conjugate high copy numbers of therapeutics, pH responsive or enzyme cleavable drug cargo. Also described herein is a design strategy for generation of synthetic RNA oligonucleotides that can self assemble into highly thermostable RNA structures. Also described herein are uses of the RNA nanostructures described herein.

First claim

What is claimed is:

1. An RNA nanostructure comprising: at least three synthetic RNA oligonucleotides,
wherein the at least three synthetic RNA oligonucleotides are coupled to each other to form a central core domain and at least three double-stranded arms arranged around the core domain and extending away from the central core domain,
wherein at least 3 cargo compound molecules are conjugated to each of the at least three synthetic RNA oligonucleotides,
wherein the melting temperature of the RNA nanostructure with the conjugated 3 to 100 cargo compounds is greater than 65 degrees Celcius, and
wherein the at least three synthetic RNA oligonucleotides are configured to self-assemble to form the RNA nanostructure.

2. The RNA nanostructure of claim 1 , wherein the RNA nanostructure comprises three to nine synthetic RNA oligonucleotides and three to nine double stranded arms.

3. The RNA nanostructure of claim 1 , wherein one or more of the at least three synthetic RNA oligonucleotides comprises one or more nucleotides modified with an alkyne or a linker.

4. The RNA nanostructure of claim 1 , further comprising a functional group attached to a nucleotide of one or more of the at least three synthetic RNA oligonucleotides, wherein the cargo compound is conjugated to the functional group.

5. The RNA nanostructure of claim 1 , wherein each of the at least three synthetic RNA oligonucleotides comprises a oligonucleotide sequence having a sequence that is at least 80% identical to any one of SEQ ID NOS: 1-54.

6. The RNA nanostructure of claim 1 comprising:
a central core, wherein the central core comprises a first modular RNA motif;
a first layer, wherein the first layer comprises at least three modular RNA motifs, wherein each of modular RNA motifs in the at least three modular RNA motifs of the first layer is attached to the first modular RNA motif; and
a second layer, wherein the second layer comprises at least three modular RNA motifs, wherein each of the at least three modular RNA motifs of the second layer is attached to a modular RNA motif of the at least three modular motifs of the first layer.

7. The RNA nanostructure of claim 6 , wherein the first modular RNA motif has a greater Tm then the modular RNA motifs of the first layer and the modular RNA motifs of the second layer.

8. The RNA nanostructure of claim 7 , wherein the modular RNA motifs of the first layer have a greater Tm than the modular RNA motifs of the second layer.

9. The RNA nanostructure of claim 1 , wherein the cargo compound is an anti-cancer compound, a chelator, radioactive isotope, a fluorophore, an miRNA, an anti-miRNA, an siRNA, a pH responsive prodrug, an enzyme cleavable prodrug, or any combination thereof.

10. The RNA nanostructure of claim 1 , comprising at least two different types of cargo compounds.

11. The RNA nanostructure of claim 1 , wherein at least 4 cargo compound molecules are conjugated to each synthetic RNA oligonucleotide.

12. The RNA nanostructure of claim 1 , wherein at least 6 cargo compound molecules are conjugated to each synthetic RNA oligonucleotide.

13. The RNA nanostructure of claim 1 , wherein the RNA nanostructure comprises four synthetic RNA oligonucleotides coupled to each other to form a central core domain and four double-stranded arms arranged around the core domain and extending away from the central core domain.

14. The RNA nanostructure of claim 13 , wherein at least 3 cargo compound molecules are conjugated to each of the four synthetic RNA oligonucleotides.

15. The RNA nanostructure of claim 13 , wherein at least 4 cargo compound molecules are conjugated to each of the four synthetic RNA oligonucleotides.

16. The RNA nanostructure of claim 13 , wherein at least 6 cargo compound molecules are conjugated to each of the four synthetic RNA oligonucleotides.

17. The RNA nanostructure of claim 1 , wherein the cargo compound is a hydrophobic small molecule compound.

18. The RNA nanostructure of claim 17 , wherein the cargo compound comprises paclitaxel.

19. The RNA nanostructure of claim 1 , wherein the cargo compound is conjugated to the at least three synthetic RNA oligonucleotides by a thermodynamic, acid-labile, light-sensitive, or enzyme-labile chemical group.

Assignees

• Ohio State Innovation Foundation
• Univ Kentucky Res Found

Inventors

• Guo Peixuan
• Vieweger Mario
• Li Xin
• Guo Sijin
• Yin Hongran
• Piao Xijun
• Shu Yi
• Shu Dan
• Rajabi Mehdi

Classifications

• C07H21/02 Primary

  with ribosyl as saccharide radical · CPC title

• A61K47/549

  Sugars, nucleosides, nucleotides or nucleic acids · CPC title

• A61K47/55

  the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug · CPC title

• C12N15/115

  Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title